Skip to content | Skip to institutional links

Common menu bar links

Institutional links

Diseases & Conditions

Health & Safety

Research & Statistics

Surveillance

Agency Information

Proactive Disclosure

Search Box

Table of Contents

E-mail this page

Chapter 5
Methodological Appendix

Table 5A-1 Drug categories
Drug Category	Drugs Included in Each Category
NSAIDs
Conventional	Diclofenac Diflunisol Etodolac Fenoprofen Flurbiprofen Ibuprofen Indomethacin Ketoprofen Ketorolac	Mefenamic Acid Nabumetone Naproxen Oxaprozin Piroxicam Sulindac Tenoxicam Tiaprofenic Acid Tolmetin
COX-2 Inhibitors	Celecoxib	Rofecoxib
Corticosteroids	Betamethasone Cortisone Dexamethasone Hydrocortisone	Methylprednisolone Prednisone Prednisolone Triamcinolone
DMARDs	Auranofin Aurothioglucose Azathioprine Chloroquine Cyclosporine Hydroxychloroquine Sulfate	Leflunomide Methotrexate Sodium Aurothiomalate D-Penicillamine Sulfasalazine
N.B. The above listed drugs may have different coverage status in different provinces

Table 5A-2 Details of provincial drug plans as of January 2003
Provinces	Who is Covered
British Columbia	People 65 years of age and older Residents of licensed long-term care facilities Residents eligible for British Columbia benefits (i.e. social assistance) Chronic disease patients (e.g. registered with a provincial Cystic Fibrosis Clinic) Low-income families Residents of the province under the age of 65 registered under the Medical Services Plan of British Columbia (once a deductible has been reached) Children eligible for medical or full benefits through the At Home Program of the Ministry for Children and Family Development Clients eligible for benefits through mental health centres Seniors have maximum contribution limits of $200-$275 depending on their incomes, while all other families are insured against “catastrophic” drug bills of over $2,000 per year.
Alberta	Alberta residents aged 65 and older All recipients aged 55-64 of the Alberta Widows' Pension and their dependents Subscribers are responsible for paying 30% of the cost, to a maximum of $25 for each prescription drug (some exceptions do exist for low income individuals).
Saskatchewan	All Saskatchewan residents are eligible for coverage under the Saskatchewan Prescription Drug Plan with the exception of those whose drug costs are covered by the federal government (e.g. Registered Indians).
Manitoba	Any Manitoban, regardless of age, whose income is seriously affected by high prescription drug costs; coverage is based on both total family income and the amount paid for eligible prescription drugs.
Ontario	People 65 years of age and over Residents of long-term care facilities Residents of Homes for Special Care People receiving professional services under the Home Care Program Social assistance recipients (General Welfare or Family Benefits Assistance)
Quebec	People 65 years of age and over People under 65 years who are not covered by a group plan and are not recipients of employment assistance (welfare)

References

1. Russell A, Haraoui B, Keystone E, Klinkhoff A. Current and emerging therapies for rheumatoid arthritis, with a focus on Infliximab: clinical impact on joint damage and cost of care in Canada. Clinical Therapeutics 2001;23(11):1824-38.

2. Schiff M. Emerging treatments for rheumatoid arthritis. Am J Med 1997;102(suppl 1A):11S-15S.

3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis; the CLASS study: a randomized controlled trial. JAMA 2000;284(10):1247-55.

4. Osiri M, Moreland LW. Specific cyclooxygenase 2 inhibitors: a new choice of nonsteroidal anti-inflammatory drug therapy. Arthritis Care Res 1999;12(5):351-62.

5. Everts B, Wahrborg P, Hedner T. COX-2-specific inhibitors - the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol 2000;19:331-43.

6. FitzGerald GA, Patrono C. The Coxibs, selective inhibitors of Cyclooxygenase-2. N Engl J Med 2001;345(6):433-42.

7. Hernandez-Diaz S, Garcia-Rodriquez LA. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001;110(3A):20S-27S.

8. Lisse J, Espinoza L, Zhao SA, Dedhiya SD, Osterhaur JT. Functional status and health-related quality of life of elderly osteoarthritic patients treated with Celecoxib. J Gerontol 2001;56A(3):M167-M175.

9. Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2-specific inhibitors. Am J Med 2001;110(3A):6S-12S.

10. Neeck G. Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis. Ann N Y Acad Sci 2002;966:28-38.

11. Caldwell JR. Intra-articular corticosteroids. Guide to selection and indication for use. Drugs 1996;52(4):507-14.

12. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology 2001;40:1211-20.

13. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding Leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Arthritis Rheum 2002;47(6):655-61.

14. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.

15. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41(5):778-99.

16. Tugwell P. Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology 2000;39(Suppl 1):43-47.

17. Callahan LF. The burden of rheumatoid arthritis: facts and figures. J Rheumatol 1998;25(Suppl 53):8.

[Previous] [Table of Contents] [Next]